PaulJ.HeskethMD

Oncology • Burlington, MA

Chair, Lahey Health Cancer Institute and Professor, Medicine, Tufts Medical Center

Join to view full profile

Dr. Hesketh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hesketh's full profile

Already have an account?

Office
Mall Rd
# 41
Burlington, MA 01805
Phone+1 781-744-8400

Fax+1 781-744-5245

Summary

I am a board certified oncologist and Chair of Lahey Health Cancer Institute in Burlington, Massachusetts.

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1983
St Elizabeth's Medical CenterResidency, Internal Medicine, 1978 - 1981
Uconn School Of MedicineClass of 1978

Certifications & Licensure

NH State Medical License 2024 - 2026
MA State Medical License 1980 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Boston Magazine Castle Connolly, 2010-2013
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2001 Nov 01
Completed
Phase 2
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 2
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 2
Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy Start of enrollment: 2008 Apr 01
Completed
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network Start of enrollment: 2010 Nov 01
Terminated
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
Recruiting
Phase 3
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Start of enrollment: 2020 Jul 20
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

167 citations
Antiemetics: ASCO Guideline Update.
Paul J. Hesketh, Mark G. Kris, Ethan Basch, Kari Bohlke, Sally Y. Barbour
Journal of Clinical Oncology. 2020-07-13
123 citations
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Ethan Basch, Ann Alexis Prestrud, Paul J Hesketh, Mark G Kris, Petra C Feyer
Journal of Clinical Oncology. 2011-11-01
6 citations
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
Karin Jordan, Alexandre Chan, Richard J Gralla, Franziska Jahn, Bernardo Rapoport
Supportive Care in Cancer. 2023-12-22